SAM
ABUS icon

Silphium Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Silphium Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33,195
Closed -$242K – 132
2018
Q2 		$242K Buy
+33,195
New +$198K 0.08% 84

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Silphium Asset Management's ABUS Position: Q3 2018 in Review

Silphium Asset Management sold out of Arbutus Biopharma (ABUS) in Q3 2018, closing a stake of 33,195 shares — an estimated $242K sold.

Silphium Asset Management first reported a position in ABUS in Q2 2018 and held it in 1 quarter. The position peaked at $242K in Q2 2018. 88 funds tracked by Wall St. Rank hold ABUS as of Q3 2018.

  • Silphium Asset Management reported no remaining Arbutus Biopharma position as of Q3 2018 after selling out during the quarter.
  • Silphium Asset Management sold 33,195 Arbutus Biopharma shares in Q3 2018, an estimated $242K.
  • Silphium Asset Management first reported a position in Arbutus Biopharma in Q2 2018 and held it in 1 quarter.
  • Silphium Asset Management's Arbutus Biopharma position peaked at $242K in Q2 2018.
  • 88 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2018.

Based on Silphium Asset Management's 13F filing for Q3 2018, filed 30 Jan 2025.